Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02725593 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT02725593 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 72 participants.
The verdict
NCT02725593, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
Interventions
- DRUG Dapagliflozin
- DRUG Dapagliflozin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-06-22 |
| Est. Completion | 2020-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02725593
The ClinicalTrials.gov registry entry for NCT02725593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT02725593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02725593 about?
NCT02725593 is a clinical study titled "Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years". A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
What is the current status of trial NCT02725593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2016-06-22. Estimated completion is 2020-04-06.
What interventions are being tested in trial NCT02725593?
The interventions under investigation include: Dapagliflozin (DRUG), Dapagliflozin placebo (DRUG).
Who is sponsoring clinical trial NCT02725593?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.